SupplementaryTable S1. Detailedclinicalandpathologicalfeatures of all the cases included in thestudy

Case Age/ OS B PS Hb Plt Leuk Lym FACS Alb ESR LDH B2M Monocl Stage EN>1 BM IPI MIPI Diff CD5* Ki67 SOX11 IgM/IgD Gender sympt (ECOG) aberrant comp IHC IHC IHC lym (%) (%) MALD1-1 66/M 71A No 0 168 219 7.0 3.9 19 46 2 297 1.78 No IV No Pos 2 3 NA Pos 5 Neg NA MALD1-2 65/M 186A No 0 162 179 8.4 3.7 53 38 2 287 1.50 No IV Yes Pos 3 3 NA Pos NA NA Yes/Yes MALD1-3 64/M 54A No 0 156 183 12.1 7.9 69 49 8 248 2.01 No IV Yes Pos 2 4 No Pos 5 Neg Yes/Yes MALD1-4 45/M 102A No 0 155 200 14.2 9.1 56 49 3 304 1.39 No IV Yes Pos 2 3 No Pos 5 Neg Yes/Yes MALD1-5 69/F 161A No 0 138 291 8.1 3.1 27 47 31 327 2.6 IgM L IV No Pos 2 4 No Neg 3 Neg Yes/Yes MALD1-6 60/F 50A No 0 137 189 11.9 8.1 63 48 12 365 1.57 No IV No Pos 2 5 NA Pos 4 Neg Yes/Yes MALD1-7 57/M 69A No 0 170 174 18.8 6.9 11 44 3 391 1.3 IgG L IV No Pos 2 6 NA Pos NA NA NA MALD1-8 48/M 101A No 0 165 207 13.9 6.5 34 44 15 453 2 No IV No Pos 1 2 NA Pos NA NA NA MALD1-9 53/F 58A No 0 123 343 13.4 8 76 46 30 198 1.9 No IV No NA 1 4 NA Neg NA NA NA MALD1-10 70/F 131A No 0 130 114 8.6 3.7 34 46 14 180 1.8 No IV No NA 2 5 NA Neg NA NA NA MALD1-11 45/F 94A No 0 142 367 14.1 3.8 63 42 18 183 1.5 No IV No Pos 1 3 NA Pos NA NA NA MALD1-12 47/F 64A No 0 130 114 15.7 12.2 57 40 7 318 1.4 No IV No Pos 1 4 No Pos NA NA NA MALD1-13 75/M 26A No 0 172 253 9.2 3.9 19 44 15 141 2 No IV No NA 2 3 NA Pos NA NA NA MCL-1 67/M 39D No 2 91 183 19.1 11 75 24 77 284 5.06 No IV Yes Pos 4 7 NA Pos NA NA Yes/Yes MCL-2 49/F 130A No 0 129 116 7.1 3.3 NA 40 NA 337 3.9 No IV No Pos 1 2 Yes Pos 15 Pos Yes/Yes MCL-3 79/F 4D Yes 1 67 78 7.6 3.6 NA 39 140 485 5 No IV No Pos 3 6 NA Pos NA NA Yes/Yes MCL-4 70/F 101D No 1 99 126 10.8 4.4 NA 33 60 505 10.1 No IV Yes Pos 4 7 Yes Pos 25 Pos Yes/Yes MCL-5 72/F 37D Yes 1 95 88 17.5 12.1 NA 39 25 441 7.60 No IV Yes Pos 3 7 Yes Pos 35 Pos Yes/Yes MCL-6 75/M 130A No 2 117 363 8.5 3.7 0 34 51 256 8.08 IgG L IV Yes Neg 3 6 No Pos 15 Pos Yes/Yes MCL-7 63/F 62AD No 1 114 97 3.8 1.6 0 38 47 295 2.36 No I No Neg 1 2 No Pos 20 Pos Yes/Yes MCL-8 69/F 74A No 0 117 352 7.2 1.6 0.5 38 66 235 2.55 No III No Neg 2 3 No Pos 15 Pos Yes/Yes MCL-9 42/M 76A No 0 163 402 8.9 2.4 10 49 9 322 1.7 No IV No Pos 1 2 No Pos 10 Pos Yes/Yes MCL-10 42/M 76AD No 0 156 189 8.2 3.5 50 42 NA 230 3.16 No IV Yes Pos 2 1 Yes Pos 20 Pos Yes/Yes MCL-11 50/F 72A No 0 135 157 6.3 0.7 13 42 NA 328 2.04 No IV No Pos 1 2 Yes Pos 20 Pos Yes/Yes MCL-12 80/M 87D No 1 147 241 8.8 2.7 NA 44 30 332 NA No I No Pos 1 5 Yes Pos 35 Pos Yes/Yes MCL-13 65/F 60A No 0 134 226 6.4 2.4 3 36 20 134 1.6 No IV Yes Pos 3 2 No Pos 20 Pos Yes/No MCL-14 82/F 17AD Yes 2 78 50 23.8 20.4 86 35 7 539 5.5 IgG L IV Yes NA 4 10 NA Pos NA NA NA MCL-15 39/M 23A No 0 146 210 87.2 68.9 NA 37 25 292 0.22 No IV No Pos 1 2 Yes Pos NA NA NA MCL-16 40/F 23A No 0 144 221 25.5 20.3 NA 40 20 139 0.18 IgM K IV No Pos 3 3 No Pos NA NA NA MCL-17 75/M 14A Yes 1 112 168 5.8 4.5 NA 38 85 159 5.9 No IV No Pos 1 3 No Pos NA NA NA MCL-a1 57/M 18D No 1 99 69 12.5 7.5 18 23 NA 1293 NA No IV Yes Pos 3 6 No Pos 5 NA NA MCL-a2 72/F 55D No 1 89 1 78 68 94 43 NA 240 4.7 NA IV No Pos 2 6 NA NA NA NA NA MCL-a3 51/M 31A No 0 154 237 7.6 2.9 9 49 27 413 2.35 No IV Yes Pos 2 3 No Pos 40 Pos NA MCL-a4 67/M 39A No 0 116 226 6.6 1.7 20 47 31 278 1.78 No IV Yes Pos 3 2 No Pos 35 Pos NA MCL-a5 75/M 24D No 0 143 104 9.1 5.6 25 40 7 627 1.79 No IV Yes Pos 4 7 Yes Pos NA NA NA MCL-a6 90/M 12AD No 3 103 109 5.9 2.6 14 26 NA 510 6.56 No IV No Pos 4 7 NA Pos NA NA NA MCL-a7 51/M NA No 0 152 227 9 1.7 8.3 40 18 194 NA No IV No Pos 1 2 NA Pos NA NA NA MCL-a8 59/M NA Yes 1 139 145 6.5 1.5 4.9 45 17 320 2.8 No IV Yes Pos 2 2 NA Pos NA NA NA MCL-a9 79/M NA Yes 2 139 88 5 2.1 2.2 34 43 354 4.2 No IV Yes Pos 4 6 NA Pos NA NA NA MCL-a10 84/M 3 Yes 1 131 231 6.8 1.6 4.8 35 24 169 0.8 No IV Yes Pos 3 4 No Pos 50 NA NA MCL-a11 46/F NA No 0 145 215 6.8 2.1 0.9 44 31 221 NA No IV Yes Pos 2 1 NA Pos NA NA NA MCL-a12 61/M 18 No 0 142 198 4.2 1.3 0.6 30 12 145 0.2 No IV No Pos 2 2 NA Pos 20 NA NA MCL-a13 60/M NA No 2 107 232 11.8 3.6 15 32 61 243 6.8 No IV Yes Pos 3 6 NA Pos NA NA NA

MALD1, monoclonal asymptomatic lymphocytosis cyclin D1 positive; MCL, mantle cell lymphoma; MCL-a, mantle cell lymphoma additional cases; OS, overall survival in months(A, Alive; AD, Alive with disease; D, Dead); B sympt, B symptoms; PS, performance status; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin (g/L); Plt, platelet count (x109/L); Leuk, leukocyte count (x109/L); Lym, lymphocyte count (x109/L); FACS aberrant lym (%), percentage of aberrant lymphoocytes detected by FACS; Alb, albumin (g/L); ESR, erythrocyte sedimentation rate (mm); LDH, lactate dehydrogenase (IU/L); B2M, beta-2 microglobulin (mg/L); Monocl comp, monoclonal component; EN, extranodal involvement; BM, bone marrow infiltration by histology or cytology; IPI, international prognostic index; MIPI, MCL international prognostic index; Diff, diffuse pattern in lymphoid tissue; *Assessed by immunohistochemistry and/or flow cytometry; NA, not available. SupplementaryTable S2. Detailedflowcytometric, cytogeneticand molecular findings of all the cases included in thestudy

Case CD23 FMC7 CD43 Lack/ CD38 CD200 ConventionalCytogenetics t(11;14) Complex PCR PCR IGH IGHV IGHV Identity Antigen SOX11 dim (%) (%) alone, karyotype MTCIGH/ mutational gene (%) driven** qRT-PC surf CGC CCND1 status R§ Ig MALD1-1 Neg Pos Neg No 22 36 46,XY,t(11;14)(q13;q32),i(17)(q10)[7]/46,XY[13]* No No Pos Clonal Mutated V4-4 97.19 No 6.5 MALD1-2 Pos Neg NA No 9 5 46,XY,t(11;14)(q13;q32)[11]/46,XY[9] Yes No Pos Clonal Mutated V4-59 96.49 No 70.6 MALD1-3 Neg Pos Neg No 35 4 46,XY,t(11;14)(q13;q32)[4]/46,XY [16] Yes No Neg Clonal Mutated V3-23 91.67 Yes 100.4 MALD1-4 Posdim Pos NA No 18 11 46,XY,t(11;14)(q13;q32)[10]/46,XY[10] Yes No Neg Clonal Mutated V4-34 95.09 No 32.9 MALD1-5 Neg Pos Neg No 25 NA 46,XX,t(11;14)(q13;q32)[6]/46,XX[14] Yes No Neg Clonal Mutated V5-51 94.79 No 1 MALD1-6 Pos Pos Neg No 29 87 46,XX,t(11;14)(q13;q32)[13]/ Yes No Pos Clonal Mutated V3-30 94.79 No 60.7 92,XXXX,t(11;14)(q13;q32)x2[2]/46,XX[5] MALD1-7 Neg Pos Neg No 1 6 46,XY,t(11;14)(q13;q32)[6]/47,XY,t(11;14)(q13;q32), No No Pos Clonal Mutated V4-59 91.23 No 42 +12[2]/46,XY[12] MALD1-8 Neg Neg NA No 5 50 46,XY,add(2)(q24),add(8)(q24),t(11;14)(q13;q32)[3]/ No Yes Neg Clonal Mutated V4-39 97.94 No 15 46,XY[25] MALD1-9 Neg Pos Neg No 34 51 46,XX,t(11;14)(q13;q32)[12]/46,XX[8] Yes No Neg Clonal Mutated V3-30 90.28 NA 1.1 MALD1-10 Neg Pos Neg No 0 0 46,XX,t(11;14)(q13;q32)[4]/46,XX[26] Yes No Neg Clonal Mutated V5a 92.71 No 0.8 MALD1-11 Pos Pos Neg No 2 95 46,XX,t(11;14)(q13;q32)[7]/46,XX[20] Yes No Pos Clonal Mutated V4-59 94.39 No 10.1 MALD1-12 Neg Pos Neg No 2 3 46,XX,t(11;14)(q13;q32)[13]/46,XX[7] Yes No Neg Clonal Unproduct. V1-nl1 0.4 MALD1-13 Pos NA Pos No 14 36 46,XY,t(11;14)(q13;q32)[4]/47,XY, No No Neg Clonal Mutated V4-34 95.79 NA 9.3 t(11;14)(q13;q32),+12[2]/ 46,XY[31] MCL-1 Neg Pos Neg No 10 0 47-48,XY,+3,del(11)(p11),t(11;14)(q13;q32), No Yes Pos Clonal Mutated V3-48 96.88 Yes 80.5 inv(15)(p13q21)x2[6]/46,XY[14] MCL-2 Pos Neg NA No 93 NA 46,XX,t(11;14)(q13;q32)[1]/46,XX[49] Yes No Neg Clonal Unmutated V1-8 98.60 - 453.7 MCL-3 Posdim Pos NA No 92 NA 46,XX[20] NA No Pos Clonal Unmutated V5-51 98.96 - 441.5 MCL-4 Neg Pos NA No 95 NA 46,XX,del(1)(q24),add(4)(p16),add(7)(q36),del(9)(q2 No Yes Neg Clonal Unmutated V4-34 99.30 - 456.6 2),t(11;14)(q13;q32)[3]/46,XX[17] MCL-5 Pos Pos NA No 54 NA 43,XX,-8,-9,der(10),t(11;14)(q13;q32),-13,-17,+mar[6 No Yes Neg Clonal Unmutated V3-48 98.96 - 130.1 ]/46,XX[16] MCL-6 Neg NA Neg NA NA NA 46,XY [20] NA No Neg Clonal Unmutated V1-8 99.30 - NA MCL-7 Neg NA Neg No NA NA 46,XX[3] NA No Pos Clonal Unmutated V2-5 98.63 - NA MCL-8 Neg NA Neg No 50 NA No metaphases NA NA Neg Clonal Unmutated V3-30 98.96 - NA MCL-9 Posdim NA NA NA 72 NA 46,XY[20] NA No Neg Clonal Unmutated V3-48 100 - NA MCL-10 Pos Pos Pos No 9 NA 46,XY,t(11;14)(q13;q32),del(13)(q24)[5]/46,XY[15] No No Neg Clonal NA NA NA NA NA MCL-11 Neg Neg Pos No 75 NA 46,XX,t(11;14;1)(q13;q32;q36)[5]/46,XX[8] No No Neg Clonal NA NA NA NA NA MCL-12 Neg NA Pos NA NA NA NA NA NA NA NA NA NA NA NA NA MCL-13 Posdim Pos Neg No 93 NA 46,XX[10] NA No Pos Clonal NA NA NA NA NA MCL-14 Neg NA Pos No 3 0 46,XX,t(11;14)(q13;q32)[1]/44,sl,add(1)(p13p31),add No Yes Neg Clonal Mutated V2-70 90.73 Yes 0.2 (3q),del(13)(q14q22),i(17)(q10),-18,-21[15]/46,XX[26 ] MCL-15 NA NA NA NA NA NA 46,XY[22] NA No Neg Clonal Unmutated V3-48 98.61 - 1201.3 MCL-16 NA NA NA NA NA NA 46,XX,t(11;14)(q14;q32)[2]/46,XX[13] Yes No Neg Clonal Mutated V3-23 97.57 No 430.7 MCL-17 NA NA NA NA NA NA 46,XY,t(11;14)(q14;q32)[1]/46,XY[24] Yes No Neg Clonal Mutated V3-9 95.83 NA 109.7 MCL-a1 Neg Pos Neg No 92 NA 43,X,-Y,+2,t(11;14)(q13;q32),-13,-21,-22[15]/46,XY[5 No Yes Neg Clonal NA NA NA NA NA dim ] MCL-a2 Neg Pos Neg No 66 0 44-45,XX,del(1)(p21p32),-9,t(11;14)(q13;q32), No Yes Pos Clonal Unmutated V1-8 98.96 NA NA dic(17;21)(p11;p11),-21,+mar[16]/46,XX[4] MCL-a3 Neg Pos Neg No 90 1 46,XY[20] NA No Pos Clonal Unmutated V4-59 100 NA NA

MCL-a4 Neg Pos Neg No 100 1 46,XY[20] NA No Pos Clonal Unmutated V5-51 99.30 NA NA

MCL-a5 Neg Pos NA No 100 0 NA NA NA Pos Clonal NA NA NA NA NA MCL-a6 Neg Pos NA No 100 0 NA NA NA Neg Clonal NA NA NA NA NA MCL-a7 Neg NA Pos Dim 64 5 NA NA NA NA NA NA NA NA NA NA MCL-a8 Neg NA Pos No 99 0 NA NA NA NA NA NA NA NA NA NA MCL-a9 Pos dim NA Pos Dim 47 0 NA NA NA Pos Pos NA NA NA NA NA MCL-a10 Neg NA Pos Dim 51 0 NA NA NA NA NA NA NA NA NA NA MCL-a11 Neg NA Pos Dim 88 0 NA NA NA NA NA NA NA NA NA NA MCL-a12 Neg NA Pos Dim 90 0 NA NA NA NA NA NA NA NA NA NA MCL-a13 Neg NA Pos No 94 4 NA NA NA NA NA NA NA NA NA NA

MALD1, monoclonal asymptomatic lymphocytosis cyclin D1 positive; MCL, mantle cell lymphoma; MCL-a, mantle cell lymphoma additional cases; CGC, Conventional G-banding cytogenetics; NA, not available; -, not applicable as the percentage of IGHV homology was >98%; *No mutations were detected in the TP53 gene by Sanger sequencing of exons 4 to 9; **As determined by the distribution of replacement (R) and silent (S) mutations in the FR and CDR regions using the binomial distribution equation originally proposed by Chang and Casali, Immunol Today 1994.§SOX11 cut off value was 105. SupplementaryTable S3. Sequence analysis of the MTC PCR products encompassing the IGH/CCND1 junction

JH MTC De novo nucleotide Case MTC nt position(1) CCND1 MTC sequence (end) JH sequence (3) segment PCR size additions (2) (4) AACTTACTCTTTATCTGCGTGGGATGAGATTAAACT ACTACTTTGACTACTGG GCGTCTTCTTCGTGGTTTGAACGCAAGAGCTCCCT GGCACGGAACCCTGGT MALD1-1 263 491 TGGGT JH4 (0 nt) GAACACCTGGCGCTG CACCGTCTCCTCAGTAA GA AACTTACTCTTTATCTGCGTGGGATGAGATTAAACT TGGGGCCAGGGAACCC GCGTCTTCTTCGTGGTTTGAACGCAAGAGCTCCCT TTTGTACCTTCGTCGC MALD1-2 278 498 TGGTCACCGTCTCCTC JH5 (0 nt) GAACACCTGGCGCTGCCATTGGC CCAGGTAAAGT GGTAAGA

AACTTACTCTTTATCTGAGTGGGATGAGATTAAACT AGTCTTAGGCCCATC MALD1-6 288 503 GCGTCTTCTTCGTGG--TCGACCCAA-AGCTCCCTG TCAGTTGTTTGACWR ? AACACCTGGCGCTGCCATTGGCGTGAA TGGGCCCC AACTTACTCTTTATCTGAGTGGGATGAGAT AATCGGAGCTACTGT MALD1-7 202 435 ? CCAG TTGACTACTGGGGCCA AACTTACTCTTTATCTGAGTGGGATGAGATTAAACT MCL-3 207 444 GAC GGGAACCCTGGTCACC JH4 (-5 nt) GCG GTCTCCTCAGGTAAGA AACTTACTCTTTATCTGAGTGGGATGAGATTAAACT GGGTCGGGACTWCC MCL-7 212 447 GCGTCT ? TGCACG

AACTTACTCTTTATCTGCGTGGGATGAGATTAAACT GACTACTGGGGCCAGG MCL-13 213 448 GCGTCTT ACTGCCG GAACCCTGGTCACCGT JH4 (-8 nt) CTCCTCAGGTAAGA

MALD1, monoclonal asymptomatic lymphocytosis cyclin D1 positive; nt, nucleotide; (1) Position of the last nucleotide in the breakpoint region aligning to the MTC region in the germline chr.11 sequence (GenBank S77049; Segal et al, Blood 1995); (2) T-nucleotides (as defined in Jägeret al, Blood 2000, and in Welzelet al, Cancer Res 2001, are shown in bold. All align to segments in the MTC region of Chr.11 (GenBank S77049); (3) JH sequence data was compared to the germline sequences described in Welzelet al, Cancer Res 2001; (4) In brackets, number of nucleotides lost from the germline sequence at the junction end. Note the precise conservation of the JH end in MALD1 cases; (?) Indicates lack of alignment to any JH segments. SupplementaryTable S4. List of differentiallyexpressedgenesbetween MCL and MALD1 withorder of appearance in Figure 4C

OrderF Affy ID Symbol logFC P-Value adj.P-Val Description ig 4C UPREGULATED in MCL withrespect to MALD1 2914070 MYO6 2.51 1.56E-09 3.76E-06 79 myosin VI SWI/SNF related, matrixassociated, actin dependent 4021149 SMARCA1 2.048 2.16E-09 3.76E-06 77 regulator of chromatin, subfamily a, member 1 3994915 HMGB3 1.553 3.91E-08 4.54E-05 78 high-mobilitygroup box 3 3061997 PON2 2.37 3.56E-07 2.48E-04 53 paraoxonase 2 3383227 GAB2 1.506 3.46E-07 2.48E-04 149 GRB2-associated bindingprotein 2 3636522 HDGFRP3 2.749 1.31E-06 7.07E-04 81 hepatoma-derivedgrowth factor, relatedprotein 3 2347132 FNBP1L 1.93 1.42E-06 7.07E-04 54 formin bindingprotein 1-like FERM, RhoGEF (ARHGEF) andpleckstrindomainprotein 3497881 FARP1 1.983 3.45E-06 1.33E-03 80 1 (chondrocyte-derived) 2340078 CACHD1 1.34 4.30E-06 1.50E-03 76 cache domaincontaining 1 3265565 ATRNL1 2.179 5.42E-06 1.71E-03 58 attractin-like 1 2402459 STMN1 1.656 2.63E-05 5.27E-03 71 stathmin 1 3284596 PARD3 1.568 2.88E-05 5.27E-03 165 par-3 partitioningdefective 3 homolog (C. elegans) ubiquitin-conjugatingenzyme E2Q familymember 2 3636879 UBE2Q2P1 1.275 2.44E-05 5.27E-03 124 pseudogene 1 3375582 FADS3 1.199 2.76E-05 5.27E-03 116 fattyaciddesaturase 3 3239891 PDSS1 1.092 2.40E-05 5.27E-03 44 prenyl (decaprenyl) diphosphatesynthase, subunit 1 2451309 KDM5B 1.04 2.28E-05 5.27E-03 114 lysine (K)-specificdemethylase 5B cysteinerichtransmembrane BMP regulator 1 2477073 CRIM1 1.648 5.50E-05 8.69E-03 82 (chordin-like) 2659887 FYTTD1 1.101 5.99E-05 9.05E-03 146 forty-two-threedomaincontaining 1 2447066 GLUL 1.479 6.60E-05 9.56E-03 170 glutamate-ammonialigase 3220156 TXN 1.186 6.98E-05 9.72E-03 163 thioredoxin 2898746 LRRC16A 1.533 9.43E-05 1.26E-02 48 leucinerichrepeatcontaining 16A 2583014 BAZ2B 1.377 1.01E-04 0.013 55 bromodomain adjacent to zinc fingerdomain, 2B 3602004 SCAMP5 1.246 1.07E-04 0.013 73 secretorycarriermembraneprotein 5 3364095 CYP2R1 1.166 1.09E-04 0.013 46 cytochrome P450, family 2, subfamily R, polypeptide 1 2745067 ELMOD2 1.026 1.09E-04 0.013 94 ELMO/CED-12 domaincontaining 2 3258092 MARCH5 0.815 1.13E-04 0.013 121 membrane-associated ring finger (C3HC4) 5 2963859 CNR1 1.567 1.17E-04 0.013 62 cannabinoid receptor 1 (brain) 2704188 PDCD10 1.135 1.28E-04 0.013 151 programmed cell death 10 2946845 ZNF204P 0.937 1.36E-04 0.014 125 zinc fingerprotein 204 (pseudogene) 2711818 LSG1 0.997 1.80E-04 0.016 132 largesubunitGTPase 1 homolog (S. cerevisiae) 2695200 PIK3R4 0.931 1.89E-04 0.017 104 phosphoinositide-3-kinase, regulatorysubunit 4 2665199 SATB1 2.016 2.06E-04 0.017 169 SATB homeobox 1 3375545 FADS1 1.391 2.11E-04 0.017 155 fattyaciddesaturase 1 3772719 LGALS3BP 1.176 2.04E-04 0.017 30 lectin, galactoside-binding, soluble, 3 bindingprotein 3292590 PBLD 1.124 2.15E-04 0.017 45 phenazinebiosynthesis-likeproteindomaincontaining 2992926 C5orf13 1.436 2.36E-04 0.018 158 chromosome 5 open reading frame 13 2655113 KLHL24 0.88 2.34E-04 0.018 147 kelch-like 24 (Drosophila) 2828856 HSPA4 0.828 2.30E-04 0.018 109 heatshock 70kDa protein 4 3781531 CABLES1 2.499 2.61E-04 0.018 51 Cdk5 andAblenzymesubstrate 1 3983154 ZNF711 2.381 2.54E-04 0.018 42 zinc fingerprotein 711 3159483 KANK1 1.271 2.63E-04 0.018 64 KN motifandankyrinrepeatdomains 1 3362468 SBF2 1.088 2.44E-04 0.018 56 SET binding factor 2 4017212 MORC4 0.89 2.65E-04 0.018 60 MORC family CW-type zinc finger 4 3041816 DFNA5 1.081 2.78E-04 0.018 144 deafness, autosomal dominant 5 3668898 ZFP1 0.896 2.93E-04 0.019 119 zinc fingerprotein 1 homolog (mouse) 2424102 CNN3 0.993 3.02E-04 0.019 50 calponin 3, acidic 2386747 GPR137B 1.155 3.24E-04 0.02 153 G protein-coupled receptor 137B 2348060 PTBP2 0.978 3.38E-04 0.02 128 polypyrimidinetractbindingprotein 2 2649640 GFM1 0.865 3.32E-04 0.02 105 G elongation factor, mitochondrial 1 2656230 SENP2 0.86 3.35E-04 0.02 131 SUMO1/sentrin/SMT3 specificpeptidase 2 2548402 EIF2AK2 1.356 3.53E-04 0.02 40 eukaryotictranslationinitiation factor 2-alpha kinase 2 2939014 MGC39372 1.266 3.50E-04 0.02 111 hypotheticalprotein MGC39372 2900269 ZSCAN16 0.743 3.56E-04 0.02 106 zinc fingerand SCAN domaincontaining 16 3869954 ZNF321 0.876 3.73E-04 0.021 122 zinc fingerprotein 321 2724853 NSUN7 1.693 3.83E-04 0.021 59 NOP2/Sundomainfamily, member 7 3053229 ZNF680 1.135 3.92E-04 0.021 107 zinc fingerprotein 680 2643157 CDV3 0.791 3.89E-04 0.021 100 CDV3 homolog (mouse) 3486956 C13orf15 1.893 4.01E-04 0.021 157 chromosome 13 open reading frame 15 3430389 C12orf23 1.171 4.08E-04 0.021 47 chromosome 12 open reading frame 23 3404636 GABARAPL1 0.989 4.16E-04 0.021 26 GABA(A) receptor-associatedproteinlike 1 3254521 TSPAN14 0.999 4.42E-04 0.022 167 tetraspanin 14 3936550 USP18 0.956 4.50E-04 0.022 28 ubiquitinspecificpeptidase 18 2712858 UBXN7 0.834 4.49E-04 0.022 95 UBX domainprotein 7 3800070 C18orf19 1.096 4.94E-04 0.023 103 chromosome 18 open reading frame 19 2640579 PLXNA1 0.797 4.91E-04 0.023 98 plexin A1 2719656 CD38 1.505 5.09E-04 0.024 173 CD38 molecule 2706985 MRPL47 0.959 5.42E-04 0.025 136 mitochondrialribosomalprotein L47 3537164 PELI2 0.991 5.82E-04 0.026 171 pellinohomolog 2 (Drosophila) 3784509 ZNF271 0.882 5.76E-04 0.026 160 zinc fingerprotein 271 2700585 PFN2 1.351 5.97E-04 0.026 85 profilin 2 2509557 ACVR2A 0.924 6.20E-04 0.026 168 activin A receptor, type IIA 3262490 C10orf78 0.797 6.36E-04 0.026 138 chromosome 10 open reading frame 78 nudix (nucleosidediphosphatelinkedmoiety X)-typemotif 3300038 NUDT9P1 0.786 6.30E-04 0.026 38 9 pseudogene 1 2990043 PHF14 0.777 6.20E-04 0.026 108 PHD fingerprotein 14 3960478 CSNK1E 0.638 6.27E-04 0.026 150 caseinkinase 1, epsilon 3103607 GDAP1 0.823 6.75E-04 0.027 126 ganglioside-induceddifferentiation-associatedprotein 1 2700500 COMMD2 0.78 6.64E-04 0.027 130 COMM domaincontaining 2 3389529 KIAA1826 0.941 7.05E-04 0.027 90 KIAA1826 2703217 KPNA4 0.801 7.02E-04 0.027 134 karyopherinalpha 4 (importin alpha 3) 3426828 VEZT 0.902 7.22E-04 0.028 120 vezatin, adherensjunctionstransmembraneprotein 2870889 C5orf13 1.474 7.38E-04 0.028 158 chromosome 5 open reading frame 13 3428088 ACTR6 0.91 7.35E-04 0.028 123 ARP6 actin-relatedprotein 6 homolog (yeast) 2651835 GPR160 1.494 7.57E-04 0.028 32 G protein-coupled receptor 160 3245682 MAPK8 0.838 7.52E-04 0.028 145 mitogen-activatedproteinkinase 8 3128731 PNMA2 1.519 7.67E-04 0.028 66 paraneoplastic antigen MA2 3450775 KIF21A 1.19 7.85E-04 0.028 31 kinesinfamilymember 21A 2654855 ATP11B 0.716 7.99E-04 0.028 135 ATPase, class VI, type 11B UTP15, U3 small nucleolar ribonucleoprotein, homolog 2815455 UTP15 0.976 8.40E-04 0.03 129 (S. cerevisiae) 2747190 DCLK2 1.104 8.62E-04 0.03 69 doublecortin-likekinase 2 synapseassociatedprotein 1, SAP47 homolog 3970130 SYAP1 0.781 8.59E-04 0.03 142 (Drosophila) 2875419 KIF3A 1.01 8.71E-04 0.03 91 kinesinfamilymember 3A 2641577 C3orf37 0.905 8.86E-04 0.03 27 chromosome 3 open reading frame 37 2871617 TRIM36 0.941 9.30E-04 0.031 83 tripartitemotif-containing 36 3390542 RDX 1.079 9.94E-04 0.032 87 radixin 2597273 C2orf67 0.965 1.01E-03 0.032 67 chromosome 2 open reading frame 67 2704267 GOLIM4 0.889 1.01E-03 0.032 49 golgi integral membraneprotein 4 2734018 MRPS18C 0.856 1.02E-03 0.032 96 mitochondrialribosomalprotein S18C 3627042 GTF2A2 0.806 1.01E-03 0.032 92 general transcription factor IIA, 2, 12kDa 3768791 ABCA6 2.477 1.05E-03 0.032 68 ATP-bindingcassette, sub-family A (ABC1), member 6 2735409 HERC5 1.026 1.08E-03 0.032 33 hectdomainand RLD 5 2946319 HIST1H4D 0.978 1.04E-03 0.032 61 histonecluster 1, H4d 2909404 CD2AP 0.977 1.04E-03 0.032 127 CD2-associated protein 2912980 OGFRL1 0.886 1.12E-03 0.033 156 opioidgrowth factor receptor-like 1 3345157 PIWIL4 0.959 1.14E-03 0.034 154 piwi-like 4 (Drosophila) 3909354 ADNP 0.786 1.15E-03 0.034 93 activity-dependent neuroprotectorhomeobox 2610359 IRAK2 0.872 1.16E-03 0.034 101 interleukin-1 receptor-associatedkinase 2 3793588 C18orf55 0.974 1.19E-03 0.034 97 chromosome 18 open reading frame 55 SPT2, Suppressor of Ty, domaincontaining 1 (S. 3365525 SPTY2D1 0.732 1.28E-03 0.036 118 cerevisiae) 3402315 CD9 2.156 1.30E-03 0.037 166 CD9 molecule 2562529 ST3GAL5 0.978 1.33E-03 0.037 137 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 ubiquitinspecificpeptidase 14 3775686 USP14 0.78 1.35E-03 0.037 139 (tRNA-guaninetransglycosylase) 3448428 C12orf11 0.882 1.39E-03 0.037 152 chromosome 12 open reading frame 11 2465551 ZNF124 0.818 1.38E-03 0.037 115 zinc fingerprotein 124 2995811 C7orf16 1.109 1.43E-03 0.037 99 chromosome 7 open reading frame 16 2620150 ZNF660 1.018 1.44E-03 0.037 57 zinc fingerprotein 660 3573933 C14orf145 0.867 1.44E-03 0.037 41 chromosome 14 open reading frame 145 3359751 ZNF195 0.679 1.44E-03 0.037 140 zinc fingerprotein 195 2899146 HIST1H4C 1.033 1.46E-03 0.038 70 histonecluster 1, H4c 3126368 PSD3 1.787 1.48E-03 0.038 36 pleckstrinand Sec7 domaincontaining 3 2650538 NMD3 0.875 1.53E-03 0.039 133 NMD3 homolog (S. cerevisiae) 2716025 RGS12 0.914 1.58E-03 0.04 84 regulator of G-proteinsignaling 12 3329343 MDK 0.924 1.63E-03 0.04 52 midkine (neuritegrowth-promoting factor 2) 2617752 ACVR2B 0.76 1.62E-03 0.04 74 activin A receptor, type IIB 3593452 DTWD1 1.211 1.64E-03 0.04 89 DTW domaincontaining 1 3063646 ZNF3 0.585 1.67E-03 0.041 148 zinc fingerprotein 3 3273251 DIP2C 0.749 1.70E-03 0.041 86 DIP2 disco-interactingprotein 2 homolog C (Drosophila) 2529421 SGPP2 0.894 1.72E-03 0.041 112 sphingosine-1-phosphate phosphotase 2 solutecarrierfamily 16, member 4 2427469 SLC16A4 1.832 1.77E-03 0.042 24 (monocarboxylicacidtransporter 5) 2883661 NA 1.086 1.78E-03 0.042 113 NA 3601051 NEO1 0.906 1.81E-03 0.042 63 neogeninhomolog 1 (chicken) 2670948 HIGD1A 0.795 1.81E-03 0.042 162 HIG1 hypoxiainducibledomainfamily, member 1A 3178416 SPIN1 0.738 1.77E-03 0.042 65 spindlin 1 3126191 PSD3 1.967 1.84E-03 0.042 36 pleckstrinand Sec7 domaincontaining 3 3597521 APH1B 0.944 1.86E-03 0.043 35 anterior pharynxdefective 1 homolog B (C. elegans) 2356818 BCL9 0.764 1.89E-03 0.043 75 B-cell CLL/lymphoma 9 3244539 ZNF22 0.709 1.89E-03 0.043 117 zinc fingerprotein 22 (KOX 15) 3452323 SLC38A2 0.904 1.97E-03 0.044 88 solutecarrierfamily 38, member 2 2651989 SKIL 1.041 2.00E-03 0.044 143 SKI-likeoncogene 2542651 WDR35 0.86 2.01E-03 0.044 110 WD repeatdomain 35 2343511 IFI44 1.718 2.12E-03 0.045 29 interferon-inducedprotein 44 2780143 BDH2 0.903 2.10E-03 0.045 72 3-hydroxybutyrate dehydrogenase, type 2 3877221 C20orf7 0.676 2.09E-03 0.045 141 chromosome 20 open reading frame 7 3421762 RAB3IP 1.046 2.19E-03 0.047 39 RAB3A interactingprotein (rabin3) 2698565 TFDP2 0.977 2.22E-03 0.047 34 transcription factor Dp-2 (E2F dimerizationpartner 2) 2658785 FAM43A 1.626 2.27E-03 0.047 25 familywithsequencesimilarity 43, member A 3875242 CRLS1 0.64 2.31E-03 0.048 161 cardiolipinsynthase 1 3205633 MCART1 0.847 2.35E-03 0.048 102 mitochondrialcarrier triple repeat 1 3449700 FAM60A 0.767 2.36E-03 0.048 43 familywithsequencesimilarity 60, member A 3444086 KLRK1 2.536 2.41E-03 0.049 172 killer cell lectin-like receptor subfamily K, member 1 2583602 RBMS1 0.852 2.41E-03 0.049 174 RNA bindingmotif, single strandedinteractingprotein 1 2664452 ANKRD28 0.761 2.46E-03 0.049 164 ankyrinrepeatdomain 28 DOWNREGULATED in MCL withrespect to MALD1 2688717 BTLA -2.319 2.69E-06 1.17E-03 17 B and T lymphocyteassociated 2794584 GPM6A -2.521 9.99E-06 2.90E-03 22 glycoprotein M6A 2636125 CD200 -2.035 1.96E-05 5.25E-03 10 CD200 molecule 2866225 MEF2C -1.77 4.29E-05 7.46E-03 18 myocyteenhancer factor 2C 3696142 DPEP2 -0.938 5.18E-05 8.59E-03 12 dipeptidase 2 2877028 KLHL3 -0.994 1.25E-04 0.013 4 kelch-like 3 (Drosophila) phosphatidicacidphosphatasetype 2 domaincontaining 3131881 PPAPDC1B -1.33 1.53E-04 0.014 13 1B 4048241 HLA-DRB5 -1.129 1.52E-04 0.014 1 major histocompatibility complex, class II, DR beta 5 2440327 SLAMF1 -1.598 2.67E-04 0.018 8 signalinglymphocyticactivationmoleculefamilymember 1 3674559 DEF8 -0.991 6.49E-04 0.027 11 differentiallyexpressed in FDCP 8 homolog (mouse) 3922333 C21orf121 -0.898 6.74E-04 0.027 23 chromosome 21 open reading frame 121 2775909 PLAC8 -1.554 1.06E-03 0.032 2 placenta-specific 8 2766289 TMEM156 -1.338 1.08E-03 0.032 14 transmembraneprotein 156 3255938 OPN4 -0.843 1.08E-03 0.032 5 opsin 4 3808745 CCDC68 -1.231 1.25E-03 0.036 19 coiled-coildomaincontaining 68 3454841 BIN2 -1.284 1.35E-03 0.037 6 bridgingintegrator 2 2718053 USP17L6P -0.849 1.36E-03 0.037 21 ubiquitinspecificpeptidase 17-like 6 (pseudogene) 3008164 LAT2 -0.667 1.80E-03 0.042 15 linker for activation of T cells family, member 2 2362201 CD1C -1.887 2.03E-03 0.045 3 CD1c molecule solutecarrierfamily 15 (H+/peptidetransporter), member 2638728 SLC15A2 -1.357 2.12E-03 0.045 16 2 2904946 MAPK13 -0.699 2.11E-03 0.045 9 mitogen-activatedproteinkinase 13 Gardner-Rasheedfeline sarcoma viral (v-fgr) 2403215 FGR -1.16 2.24E-03 0.047 7 oncogenehomolog 2315251 OR4F16 -1.058 2.44E-03 0.049 20 olfactory receptor, family 4, subfamily F, member 16

MCL, mantle cell lymphoma; MALD1, monoclonal asymptomaticlymphocytosiscyclin D1-positive.

Supplementary Table S5. Summary of the main pathways differentially enriched in MALD1 and MCL lymphocytes

MALD1 IPA Top Networks Score InflammatoryResponse, InflammatoryDisease, CellularFunctionandMaintenance 12 CellularDevelopment, Hematological System DevelopmentandFunction, Skeletaland Muscular System DevelopmentandFunction 3 Antigen Presentation, Cell-To-Cell SignalingandInteraction, CellularGrowthandProliferation 3 CellularDevelopment, Cell Cycle, ConnectiveTissueDevelopmentandFunction 3

GSEA Results NES NOM P FDR Polycomb targets equally differentiated, resting cells BENPORATH_ES_WITH_H3K27ME3 2.74 < 0.01 < 0.01 BENPORATH_PRC2_TARGETS 2.65 < 0.01 < 0.01 REACTOME_GPCR_LIGAND_BINDING 2.71 < 0.01 < 0.01 Cytokine signalling and signal transduction REACTOME_DOWNSTREAM_EVENTS_IN_GPCR_SIGNALING 2.27 < 0.01 < 0.01 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 2.10 < 0.01 < 0.01 BIOCARTA_CYTOKINE_PATHWAY 1.92 < 0.01 < 0.01 REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES 2.25 < 0.01 < 0.01 Integrin-mediated cell migration and adhesion pathways KEGG_ECM_RECEPTOR_INTERACTION 2.04 < 0.01 < 0.01 KEGG_CELL_ADHESION_MOLECULES_CAMS 1.92 < 0.01 < 0.01 REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS 1.59 0.03 0.08 REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 1.51 0.01 0.19 B-cell activation, Immunoregulatory and Inflammatory responses KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION 2.17 < 0.01 < 0.01 KEGG_ARACHIDONIC_ACID_METABOLISM 2.04 < 0.01 < 0.01 BIOCARTA_BLYMPHOCYTE_PATHWAY 1.97 < 0.01 < 0.01 REACTOME_TRANSLOCATION_OF_ZAP70_TO_IMMUNOLOGICAL_SYNAPSE 1.85 < 0.01 0.02 BIOCARTA_INFLAM_PATHWAY 1.77 < 0.01 0.03 REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID _AND_A_NON_LYMPHOID_CELL 1.68 < 0.01 0.05 BIOCARTA_IL17_PATHWAY 1.61 0.03 0.07 BIOCARTA_IL5_PATHWAY 1.56 0.03 0.09 AUJLA_IL22_AND_IL17A_SIGNALING 1.81 < 0.01 0.02 Local acute inflammatory response BIOCARTA_LAIR_PATHWAY 2.24 < 0.01 < 0.01 V$NFKAPPAB_01 1.66 < 0.01 0.05 GGGNNTTTCC_V$NFKB_Q6_01 1.61 < 0.01 0.08

MCL IPA Top Networks Score Cell Death, Cell-To-Cell SignalingandInteraction, CellularAssemblyand Organization 23 Cell-To-Cell SignalingandInteraction, CellularDevelopment, ImmunologicalDisease 17 Cell-To-Cell SignalingandInteraction, TissueDevelopment, CellularGrowthandProliferation 15 CellularGrowthandProliferation, Hematological System DevelopmentandFunction, CellularDevelopment 12

GSEA Results NES NOM P FDR Myc pathway SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM 3.54 < 0.01 < 0.01 BENPORATH_MYC_MAX_TARGETS 2.44 < 0.01 < 0.01 DANG_MYC_TARGETS_UP 2.40 < 0.01 < 0.01 BASSO_B_LYMPHOCYTE_NETWORK 2.28 < 0.01 < 0.01 DANG_BOUND_BY_MYC 2.12 < 0.01 < 0.01 SCHUHMACHER_MYC_TARGETS_UP 2.21 < 0.01 < 0.01 YU_MYC_TARGETS_UP 2.12 < 0.01 < 0.01 WEI_MYCN_TARGETS_WITH_E_BOX 2.83 < 0.01 < 0.01 Cyclin D1 signature MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN 2.23 < 0.01 < 0.01 Wnt pathway REACTOME_SIGNALING_BY_WNT 2.88 < 0.01 < 0.01 BILD_CTNNB1_ONCOGENIC_SIGNATURE 1.74 < 0.01 < 0.01 Other oncogenic pathways SWEET_KRAS_ONCOGENIC_SIGNATURE 1.95 < 0.01 < 0.01 BILD_SRC_ONCOGENIC_SIGNATURE 1.52 0.02 0.08 Cell cycle and proliferation REACTOME_CELL_CYCLE_MITOTIC 2.95 < 0.01 < 0.01 REACTOME_MITOTIC_M_M_G1_PHASES 2.93 < 0.01 < 0.01 BENPORATH_PROLIFERATION 2.76 < 0.01 < 0.01 REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_P27_P21 2.75 < 0.01 < 0.01 REACTOME_M_G1_TRANSITION 2.70 < 0.01 < 0.01 REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_ 2.69 < 0.01 < 0.01 REACTOME_G1_S_TRANSITION 2.66 < 0.01 < 0.01 REACTOME_SYNTHESIS_OF_DNA 2.66 < 0.01 < 0.01 REACTOME_S_PHASE 2.64 < 0.01 < 0.01 REACTOME_DNA_REPLICATION_PRE_INITIATION 2.60 < 0.01 < 0.01 REACTOME_G2_M_TRANSITION 2.47 < 0.01 < 0.01 BENPORATH_CYCLING_GENES 2.34 < 0.01 < 0.01 GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 2.26 < 0.01 < 0.01 KEGG_CELL_CYCLE 2.18 < 0.01 < 0.01 DNA damage and repair pathways BIOCARTA_P53_PATHWAY 1.51 0.05 0.08 PUJANA_ATM_PCC_NETWORK 1.90 < 0.01 < 0.01 REACTOME_FANCONI_ANEMIA_PATHWAY 1.93 < 0.01 < 0.01 KAUFFMANN_DNA_REPAIR_GENES 2.38 < 0.01 < 0.01 REACTOME_P53_INDEPENDENT_DNA_DAMAGE_RESPONSE 2.56 < 0.01 < 0.01 REACTOME_CELL_CYCLE_CHECKPOINTS 2.74 < 0.01 < 0.01 REACTOME_STABILIZATION_OF_P53 2.74 < 0.01 < 0.01 BIOCARTA_ATM_PATHWAY 1.97 < 0.01 < 0.01 REACTOME_NUCLEOTIDE_EXCISION_REPAIR 1.98 < 0.01 < 0.01 KEGG_NUCLEOTIDE_EXCISION_REPAIR 1.83 < 0.01 0.02 Transcription and mRNA metabolism BIOCARTA_MTOR_PATHWAY 1.74 0.01 0.02 REACTOME_FORMATION_AND_MATURATION_OF_MRNA_TRANSCRIPT 3.14 < 0.01 < 0.01 REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA 3.11 < 0.01 < 0.01 REACTOME_ELONGATION_AND_PROCESSING_OF_CAPPED_TRANSCRIPTS 3.09 < 0.01 < 0.01 KEGG_SPLICEOSOME 3.03 < 0.01 < 0.01 REACTOME_METABOLISM_OF_RNA 3.02 < 0.01 < 0.01 REACTOME_MRNA_SPLICING 2.97 < 0.01 < 0.01 REACTOME_TRANSCRIPTION 2.80 < 0.01 < 0.01 Stem cell associated signatures RAMALHO_STEMNESS_UP 2.95 < 0.01 < 0.01 WONG_EMBRYONIC_STEM_CELL_CORE 2.63 < 0.01 < 0.01 JAATINEN_HEMATOPOIETIC_STEM_CELL_UP 2.07 < 0.01 < 0.01 HADDAD_B_LYMPHOCYTE_PROGENITOR 1.62 < 0.01 0.05 MUELLER_PLURINET 2.24 < 0.01 < 0.01 Signatures associated to hematopoietic malignancies DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP 3.39 < 0.01 < 0.01 SASAKI_ADULT_T_CELL_LEUKEMIA 1.69 < 0.01 0.03 HOFMANN_CELL_LYMPHOMA_UP 1.68 < 0.01 0.04 HADDAD_B_LYMPHOCYTE_PROGENITOR 1.62 < 0.01 0.05 HUMMEL_BURKITTS_LYMPHOMA_UP 1.52 0.04 0.08

MCL, mantle cell lymphoma; MALD1, monoclonal asymptomaticlymphocytosiscyclin D1-positive; For theGene Set EnrichmentAnalysisresults (GSEA), gene set namescorrespond to thosereferenced in theBroadInstitute Molecular SignatureDatabase (MSigDB). P and FDR valuesare as calculatedbythe GSEA tool, usinggene set permutationsanddefaultstatisticalparameters. Scores for networks significativelyenriched in theIngenuityPathwayAnalysis (IPA) arebased on a Fisher Exact Test. Onlythose networks withscores> 2 (P-value< 0.01) areshown. NES, normalizedenrichmentscore; NOM P, nominal P-value; FDR, falsediscoveryrate. SupplementaryTable S6. Table of all samplesused to generatethe CART. Classificationcolumn presents theassignedgroupafterapplyingthe CART

Case CD38 (%) CD200 (%) Classification MALD1-1 22 36 MALD1 MALD1-2 9 5 MALD1 MALD1-3 35 4 MALD1 MALD1-4 18 11 MALD1 MALD1-5 25 NA Non-Classified MALD1-6 29 87 MALD1 MALD1-7 1 6 MALD1 MALD1-8 5 50 MALD1 MALD1-9 34 51 MALD1 MALD1-10 0 0 Non-Classified MALD1-11 2 95 MALD1 MALD1-12 2 3 MALD1 MALD1-13 14 36 MALD1 MCL-1 10 0 Non-Classified MCL-2 93 NA MCL MCL-3 92 NA MCL MCL-4 95 NA MCL MCL-5 54 NA MCL MCL-8 50 NA MCL MCL-9 72 NA MCL MCL-10 9 NA Non-Classified MCL-11 75 NA MCL MCL-13 93 NA MCL MCL-14 3 0 Non-Classified MCL-a1 92 0 MCL MCL-a2 66 0 MCL MCL-a3 90 1 MCL MCL-a4 100 1 MCL MCL-a5 100 0 MCL MCL-a6 100 0 MCL MCL-a7 64 5 MCL MCL-a8 99 0 MCL MCL-a9 47 0 MCL MCL-a10 51 0 MCL MCL-a11 88 0 MCL MCL-a12 90 0 MCL MCL-a13 94 4 MCL

MALD1, monoclonal asymptomaticlymphocytosiscyclin D1-positive; MCL, mantle cell lymphoma; MCL-a, mantle cell lymphomaadditional cases; Fisher’sexact test of confusionmatrix of real andpredicted categories gave a P < 0.001.